A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2017

At a glance

  • Drugs Risankizumab (Primary) ; Risankizumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 14 Nov 2017 Planned End Date changed from 14 Feb 2020 to 12 Aug 2020.
    • 14 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 22 Sep 2017 Planned initiation date changed from 12 May 2017 to 29 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top